Ascidian starts up with $50M and a twist on RNA editing
Bio Pharma Dive
OCTOBER 12, 2022
The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA.
Let's personalize your content